Helicobacter Pylori and Proton Pump Inhibitor

December 4, 2016 updated by: Ji Yong Ahn, Asan Medical Center

Distribution of Helicobacter Pylori According to the Use of Proton Pump Inhibitor

The purpose of this study is to know the distribution of HP in stomach before use of PPI, during use of PPI, and after stop of PPI.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Endoscopy and biopsy will be performed to investigate the distrubition of HP before, during, and after using PPI.

Study Type

Observational

Enrollment (Actual)

30

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Korea, Republic of
    • Songpa-gu
      • Seoul, Songpa-gu, Korea, Republic of, 138-736
        • Asan Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

19 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Sample size will be determined based on the analysis the distribution rate of HP at first 30 patients.

Description

Inclusion Criteria:

  1. Patients who are indicated to endoscopic resection due to gastric neoplasm
  2. Aged between 19 to 65 years
  3. Informed consent

Exclusion Criteria:

  1. Previous history of HP eradication
  2. Previous history of PPI use within 6 months
  3. No HP infection

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Helicobacter pylori(HP) positive
Participants who are diagnosed with Helicobacter Pylori infection through ESD(endoscopic submucosal dissection) will be treated with PPI (proton pump inhibitor).
Drug: PPI (proton pump inhibitor)

  1. Pre ESD (endoscopic submucosal dissection)

    • Assessment atrophy and metaplasia in stomach, Check Helicobacter pylori
    • Use of PPI for 2 months

  2. Post ESD 1 (After 2 months)

    • Assess the distribution of helicobacter pylori after using PPI.
    • Stop of PPI

  3. Post ESD 2 (After 4 months)

    • Assess the distribution of helicobacter pylori after stop of PPI.
Other Names:
  • pantoprazole, lansoprazole, dexlansoprazole, rabeprazole

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Analysis the change of Helicobacter pylori distribution according to the use of proton pump inhibitor
Time Frame: Change in the distribution of Helicobacter Pylori(HP) at 4 months.
Change in the distribution of Helicobacter Pylori(HP) at 4 months.

Secondary Outcome Measures

Outcome Measure
Time Frame
Analysis the change of HP distribution according to the use of PPI in atrophic change of stomach
Time Frame: Change in the distribution of Helicobacter Pylori(HP) at 4 months.
Change in the distribution of Helicobacter Pylori(HP) at 4 months.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Asan Medical Center

Investigators

  • Principal Investigator: Ji Yong Ahn, Professor, Asan Medical Center

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

March 1, 2014

Primary Completion (Actual)

December 1, 2016

Study Completion (Actual)

December 1, 2016

Study Registration Dates

First Submitted

May 14, 2015

First Submitted That Met QC Criteria

May 18, 2015

First Posted (Estimate)

May 21, 2015

Study Record Updates

Last Update Posted (Estimate)

December 6, 2016

Last Update Submitted That Met QC Criteria

December 4, 2016

Last Verified

December 1, 2016

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2014-0341

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Helicobacter Infections

Clinical Trials on PPI (proton pump inhibitor)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Kingdom

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe